Research programme: late sodium current blockers - Gilead Sciences

Drug Profile

Research programme: late sodium current blockers - Gilead Sciences

Alternative Names: Late INA

Latest Information Update: 27 Mar 2013

Price : $50

At a glance

  • Originator CV Therapeutics
  • Class Dihydropyridines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cardiovascular disorders

Most Recent Events

  • 31 Dec 2012 Gilead advances its late sodium channel inhibitor, designated GS 6615, into clinical development for Ischaemic heart disease and Arrhythmias
  • 17 Apr 2009 CV Therapeutics has been acquired and merged into Gilead Sciences
  • 26 Mar 2009 Pharmacodynamics data from an in vitro trial presented at the 237th American Chemical Society National Meeting (237th-ACS-2009) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top